Literature DB >> 3129006

The effect of carbidopa and indomethacin on the renal response to gamma-L-glutamyl-L-dopa in normal man.

R F Jeffrey1, T M MacDonald, K Marwick, M R Lee.   

Abstract

1. The renal response to gamma-L-glutamyl-L-dopa (gludopa, 25 micrograms kg-1 min-1) was investigated in seven normal male volunteers. The effects of oral carbidopa (100 mg) and indomethacin (100 mg) on the response to gludopa were studied in the same group. 2. Gludopa at this dose level produced a 900-fold increase in urine dopamine excretion and caused a natriuresis and suppression of plasma renin activity with only minor effects on pulse rate and blood pressure. 3. Carbidopa inhibited the increase in dopamine excretion by 97% and abolished the renal actions of gludopa. 4. The increase in urine dopamine produced by gludopa was not altered by indomethacin and the urine sodium output was similar to that caused by gludopa alone. 5. Gludopa is an effective renal dopamine prodrug whose activity can be blocked by the dopa decarboxylase inhibitor carbidopa. The results with indomethacin suggest that dopamine and the prostaglandins form separate natriuretic systems in the kidney.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3129006      PMCID: PMC1386474          DOI: 10.1111/j.1365-2125.1988.tb03291.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  23 in total

1.  THE DISTRIBUTION OF DOPAMINE AND DOPA IN VARIOUS ANIMALS AND A METHOD FOR THEIR DETERMINATION IN DIVERSE BIOLOGICAL MATERIAL.

Authors:  A H ANTON; D F SAYRE
Journal:  J Pharmacol Exp Ther       Date:  1964-09       Impact factor: 4.030

2.  Evidence that renal vasodilation by dopamine in dogs does not involve release of prostaglandin.

Authors:  W E Dressler; G V Rossi; R F Orzechowski
Journal:  J Pharm Pharmacol       Date:  1975-03       Impact factor: 3.765

3.  Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects.

Authors:  E Haber; T Koerner; L B Page; B Kliman; A Purnode
Journal:  J Clin Endocrinol Metab       Date:  1969-10       Impact factor: 5.958

4.  The depressor and renal vasodilator responses to dopamine in the rat do not depend on prostaglandin biosynthesis.

Authors:  M J Robertson; N M Horn; B J Chapman
Journal:  J Pharm Pharmacol       Date:  1980-11       Impact factor: 3.765

5.  The effect of indomethacin on plasma renin activity in man under normal conditions and after stimulation of the renin angiotensin system.

Authors:  K W Rumpf; S Frenzel; H D Lowitz; F Scheler
Journal:  Prostaglandins       Date:  1975-10

6.  Renal conversion of plasma DOPA to urine dopamine.

Authors:  M J Brown; D J Allison
Journal:  Br J Clin Pharmacol       Date:  1981-08       Impact factor: 4.335

7.  Production of urine free dopamine from DOPA; a micropuncture study.

Authors:  A D Baines; W Chan
Journal:  Life Sci       Date:  1980-01-28       Impact factor: 5.037

8.  Methods for the determination of glandular kallikrein by means of a chromogenic tripeptide substrate.

Authors:  E Amundsen; J Putter; P Friberger; M Knos; M Larsbraten; G Claeson
Journal:  Adv Exp Med Biol       Date:  1979       Impact factor: 2.622

9.  Immunohistochemical localization of the prostaglandin-forming cyclooxygenase in renal cortex.

Authors:  W L Smith; T G Bell
Journal:  Am J Physiol       Date:  1978-11

10.  Increased urinary kallikrein excretion during prostaglandin E1 infusion in anaesthetized dogs and its relation to natriuresis and diuresis.

Authors:  I H Mills; L F Obika
Journal:  J Physiol       Date:  1977-12       Impact factor: 5.182

View more
  11 in total

1.  Disruption of the dopamine D3 receptor gene produces renin-dependent hypertension.

Authors:  L D Asico; C Ladines; S Fuchs; D Accili; R M Carey; C Semeraro; F Pocchiari; R A Felder; G M Eisner; P A Jose
Journal:  J Clin Invest       Date:  1998-08-01       Impact factor: 14.808

2.  The effects of intravenous L-dopa on plasma renin activity, renal function, and blood pressure in man.

Authors:  D Worth; J Harvey; J Brown; M Lee
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

3.  The pharmacokinetics of gamma-glutamyl-L-dopa in normal and anephric rats and rats with glycerol-induced acute renal failure.

Authors:  Y A Boateng; H E Barber; T M MacDonald; J C Petrie; M R Lee; P H Whiting
Journal:  Br J Pharmacol       Date:  1990-10       Impact factor: 8.739

4.  Regional haemodynamic effects of dopamine and its prodrugs L-dopa and gludopa in the rat and in the glycerol-treated rat as a model for acute renal failure.

Authors:  J C Drieman; F J van Kan; H H Thijssen; H van Essen; J F Smits; H A Struijker Boudier
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

5.  Intrarenal dopaminergic system regulates renin expression.

Authors:  Ming-Zhi Zhang; Bing Yao; Xiaofeng Fang; Suwan Wang; James P Smith; Raymond C Harris
Journal:  Hypertension       Date:  2009-01-12       Impact factor: 10.190

6.  Disposition of gamma-glutamyl levodopa (gludopa) after intravenous bolus injection in healthy volunteers.

Authors:  Y A Boateng; H E Barber; T M MacDonald; J C Petrie; M R Lee
Journal:  Br J Clin Pharmacol       Date:  1991-04       Impact factor: 4.335

7.  An increase in renal dopamine does not stimulate natriuresis after fava bean ingestion.

Authors:  Emily M Garland; Tericka S Cesar; Suzanna Lonce; Marcus C Ferguson; David Robertson
Journal:  Am J Clin Nutr       Date:  2013-04-03       Impact factor: 7.045

8.  The renal handling of dopamine originating from L-dopa and gamma-glutamyl-L-dopa.

Authors:  M Pestana; P Soares-da-Silva
Journal:  Br J Pharmacol       Date:  1994-06       Impact factor: 8.739

9.  The renal and haemodynamic effects of a 10 h infusion of glutamyl-L-dopa in normal man.

Authors:  T M MacDonald; R F Jeffrey; M R Lee
Journal:  Br J Clin Pharmacol       Date:  1989-06       Impact factor: 4.335

10.  (+)-sulpiride antagonises the renal effects of gamma-L-glutamyl-L-dopa in man.

Authors:  T M MacDonald; R F Jeffrey; S Freestone; M R Lee
Journal:  Br J Clin Pharmacol       Date:  1988-02       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.